News 

September 8, 2024

Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024

September 3, 2024

Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis

August 29, 2024

Avalyn to Participate in Multiple Upcoming Investor Conferences

August 26, 2024

Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Respiratory Society International Congress 2024

August 12, 2024

Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib

August 5, 2024

Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors

August 1, 2024

Avalyn to Participate in Multiple Upcoming Investor Conferences

May 28, 2024

Avalyn to Participate in Jefferies Global Healthcare Conference

May 20, 2024

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

May 13, 2024

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference

May 1, 2024

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer

March 6, 2024

Avalyn to Participate in Leerink Partners Global Biopharma Conference

February 6, 2024

Avalyn to Participate in Multiple Upcoming Investor Conferences

December 6, 2023

Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference

November 9, 2023

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis

November 6, 2023

Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations

October 5, 2023

Avalyn to Participate in Multiple Upcoming Investor Conferences

September 29, 2023

Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference

September 27, 2023

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

September 18, 2023

Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit